Literature DB >> 15739811

Confirmatory factor analysis of the behavioral dyscontrol scale in a mixed clinical sample.

Eric Ecklund-Johnson1, Steven A Miller, Jerry J Sweet.   

Abstract

The Behavioral Dyscontrol Scale (BDS) is a brief measure of executive functioning originally designed for use primarily with older adults. Previous research suggests that factors derived from exploratory factor analysis of the BDS have clinical utility and are theoretically meaningful; however, the factor structure has not been previously submitted to confirmatory analysis, and there are several potential methodological problems with the previous exploratory factor analysis. In this study, we conducted a confirmatory factor analysis of the BDS. Findings were largely consistent with the original exploratory analysis (Grigsby, Kaye, & Robbins, 1992) in suggesting a three-factor model, although the three-factor model was a better fit if factors were allowed to correlate with one another. The findings of this study lend support to the current practice of using factor scores in clinical and research applications.

Mesh:

Year:  2004        PMID: 15739811     DOI: 10.1080/1385404049052415

Source DB:  PubMed          Journal:  Clin Neuropsychol        ISSN: 1385-4046            Impact factor:   3.535


  2 in total

1.  Functional status of men with the fragile X premutation, with and without the tremor/ataxia syndrome (FXTAS).

Authors:  Angela G Brega; Ann Reynolds; Rachael E Bennett; Maureen A Leehey; Lanee S Bounds; Jennifer B Cogswell; Randi J Hagerman; Paul J Hagerman; Jim Grigsby
Journal:  Int J Geriatr Psychiatry       Date:  2009-10       Impact factor: 3.485

2.  The primary cognitive deficit among males with fragile X-associated tremor/ataxia syndrome (FXTAS) is a dysexecutive syndrome.

Authors:  Angela G Brega; Glenn Goodrich; Rachael E Bennett; David Hessl; Karen Engle; Maureen A Leehey; Lanee S Bounds; Marsha J Paulich; Randi J Hagerman; Paul J Hagerman; Jennifer B Cogswell; Flora Tassone; Ann Reynolds; Robert Kooken; Michael Kenny; Jim Grigsby
Journal:  J Clin Exp Neuropsychol       Date:  2008-02-15       Impact factor: 2.475

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.